Now, Samsung Bioepis and marketing partner Organon have the clinical data they need to get their Hadlima biosimilar approved as an interchangeable option and seek a leg-up in the competitive ...

In its place, the PBM included the Humira-referenced biosimilars Hyrimoz, Hadlima and adalimumab-fkjp (an unbranded product). Hyrimoz appears to be the most favored biosimilar. While removal of ...

So it was that Saturday 1st July was a busy day. Organon and Samsung Bioepsis were first to launch biosimilar Hadlima (adalimumab-bwwd) that day, at the sale price of $1,038 per carton containing ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

A majority of biosimilar gains are due to Hyrimoz (adalimumab-adaz) and Hadlima (adalimumab-bwwd). These biosimilars have provided the market with diverse WAC pricing options that offer reduced ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

The South Korean drugmaker added that Hyrimoz and Hadlima, Humira biosimilars marketed by CVS Health (CVS)/Sandoz (SDXNY) (OTCQX:SDZXF) and Organon (OGN)/Samsung Bioepis, respectively, have led to ...

However, according to Samsung Bioepis, ABBV continues to claim 72% of the adalimumab market in the U.S. as of November, even as its biosimilars have gained ground, claiming 23% of the market ...